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Introduction: Antibodies are synthesized in mammalian cell culture as heterogeneous mixtures of glycoforms. 
Therefore the glycan profile of monoclonal antibodies harvested from a bioreactor consists of various glycans 
depending upon the culture media, the control parameters and the metabolic status of the cells.    Isolation of 
single glycoforms remains a challenge despite their value as agents of specific biological function.  We report a 
method of sequential enzymatic-based changes to antibodies while trapped on an affinity column following 
harvest from a bioreactor.  This method of solid phase enzymatic transformation is superior to previously 
reported methods because it allows a series of enzymatic steps without the need for intermediate purification of 
the antibody.    
 
Results: Antibodies (camelid, Cetuximab and polyclonal human) were isolated on a solid-phase lectin column 
and their glycans modified by a sequential addition of enzymes for a desired transformation. Galactosylated 
antibodies (>90% yield) were produced by a two stage reaction. Sialylated antibodies (>90%) were produced by 
a 3 stage reaction involving sialidase, galactosyltransferase and finally treatment with the 2,6 sialyltransferase in 
the presence of CMP-NANA. Equimolar quantities of monosialylated and disialylated forms of the human 
antibodies (150 kDa) were produced and the results suggest that further sialylation may be limited by steric 
constraints within the dimeric structure. The ability to sialylate the smaller camelid antibody (80 kDa) was much 
greater with a high (>90%) yield of disialylated glycan structures, indicating that the steric constraints were less.  
 
Significance: The biological activity of an antibody is highly dependent upon the glycan structure, which is 
described as a critical quality attribute for clinical efficacy.  It is well reported that non-fucosylated or low 
galactosylated antibodies have high antibody-dependent cellular cytoxicity (ADCC). Sialylated antibodies have 
significant activity as ant-inflammatory agents.  Therefore, isolating a single glycoform targeted for a specific 
biological activity offers considerable advantages.  The method described in this abstract of enzymatic 
transformation during antibody purification provides a relatively simple solution to obtaining single glycoforms 
without the need for complex control during bioprocessing.  
 
